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Abstract 
Objectives: Tenofovir is associated with reduced renal function. It is not clear whether 
patients can be expected to fully recover their renal function if tenofovir is discontinued. 
Methods: We calculated the estimated glomerular filtration rate (eGFR) for patients in the 
Swiss HIV Cohort Study remaining on tenofovir for at least one year after starting a first 
antiretroviral therapy with tenofovir and either efavirenz or the ritonavir boosted protease 
inhibitors lopinavir, atazanavir or darunavir. We estimated the difference in eGFR slope 
between those who discontinued tenofovir after one year and those who remained on 
tenofovir. 
Results: 1049 patients on tenofovir for at least one year were then followed for a median of 
26 months, during which time 259 (25%) patients discontinued tenofovir. After a year on 
tenofovir, the difference in eGFR between those starting with efavirenz and those starting with 
lopinavir , atazanavir and darunavir was -0.7 (95% confidence interval (CI) -2.3 to 0.8), -1.4 
(95% CI -3.2 to 0.3) and 0.0 (95% CI -1.7 to 1.70) mL/min per 1.73 m2 respectively. The 
estimated linear rate of decline in eGFR on tenofovir was -1.1 (95% CI -1.5 to -0.8) mL/min 
per 1.73 m2 per year and its recovery after discontinuing tenofovir was 2.1 (95% CI 1.3 to 2.9) 
mL/min per 1.73 m2 per year. Patients starting tenofovir with either lopinavir or atazanavir 
appeared to have the same rates of decline and recovery as those starting tenofovir with 
efavirenz. 
Conclusions: If patients discontinue tenofovir, clinicians can expect renal function to recover 
more rapidly than it declined. 
 
Keywords: HIV, highly active antiretroviral therapy, kidney glomerulus, proximal kidney 
tubules 
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Introduction 
Tenofovir disoproxil fumarate (tenofovir) co-formulated with emtricitabine is the preferred 
reverse transcriptase inhibitor combination for patients with HIV when starting antiretroviral 
therapy [1]. Tenofovir is mainly eliminated by the kidneys and its use is associated with 
reduced renal function [2]. Regular monitoring of renal function is recommended for all 
patients on tenofovir [1]. 
While early reports suggest that renal function recovers completely when patients 
discontinue tenofovir [3,4], larger recent studies suggest that some patients do not fully 
recover. In one study, only 42% of 24 patients recovered their pre-tenofovir estimated 
glomerular filtration rate (eGFR) [5]; in another, 59% of 183 patients returned to normal levels 
of eGFR but the time taken to recover varied considerably, with a mean of 22 months and an 
interquartile range (IQR) of 13 to 50 months [6]. 
It is difficult to estimate the rate of decline in eGFR for patients on tenofovir and its 
subsequent recovery if tenofovir is discontinued. First patients with lower eGFR are more 
likely to discontinue tenofovir [7]. Second the rate of recovery may well be greater in those 
patients who had a faster decline in eGFR [5]. These two factors create the potential for time 
dependent confounding, so that standard methods of analysis may lead to biased estimates 
[8]. 
In this study, we use marginal structural models to overcome the bias of standard 
methods. Using observational data from the Swiss HIV Cohort Study (SHCS), we estimate 
the rate of decline in eGFR for patients on tenofovir and the subsequent rate of recovery if 
tenofovir is then discontinued. 
Methods 
Patients 
The SHCS is a multi-centre, prospective, observational cohort study with continuing 
enrolment of HIV-infected adults and routine follow up scheduled every 6 months [9]. In our 
study we included all patients starting their first antiretroviral therapy after 1 January 2002, 
when routine measurement of serum creatinine measurements began in the SHCS. Patients 
had to start with tenofovir and either efavirenz (EFV) or the ritonavir boosted protease 
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inhibitors (PI/r) lopinavir (LPV/r), atazanavir (ATV/r) or darunavir (DRV/r), plus either 
emtricitabine or lamivudine. Patients had to then remain on tenofovir for at least one year – 
otherwise we could not expect any decline in eGFR nor subsequent recovery if the use of 
tenofovir then ceased – and have at least one calibrated serum creatinine measurement 
between 6 months and one year after starting therapy. We included in our analyses all 
measurements from the baseline at one year after starting therapy until the last recorded 
measurement to date or until patients re-started tenofovir having previously discontinued the 
drug, whichever came first. We calculated eGFR (in ml/min per 1.73m2) using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula [10]; we used only calibrated 
measurements because different SHCS centres use different measurement techniques.  
Statistical analyses 
We estimated the difference in eGFR over time between patients discontinuing tenofovir and 
patients remaining on tenofovir using marginal structural models for repeated measures 
[8,11]. These models used inverse probability weights for confounder control: treatment 
weights to adjust for differences in patients discontinuing or remaining on tenofovir over time; 
censoring weights to adjust for differences between patients continuing to provide 
measurements over time and those lost to follow up or re-starting tenofovir. Inverse 
probability weights were estimated by logistic regression using covariates likely to determine 
whether patients discontinued or re-started tenofovir or were lost to follow up: gender, 
ethnicity, injection drug use as the likely mode of transmission, age at baseline and initial 
antiretroviral regimen (EFV, LPV/r, ATV/r or DRV/r); and time-updated measurement of 
diabetes, hepatitis C co-infection, hypertension, body mass index, viral load, CD4 cell count 
and eGFR. We avoided extreme weights by truncating inverse probability weights at their 1st 
and 99th percentiles if below or above these values respectively [12]. 
In our main analysis, we fitted a sequence of three models. In Model 1, we used a cubic 
spline [13] to represent the decline in eGFR over time for patients remaining on tenofovir and 
a piecewise linear spline [14] to represent the difference in eGFR for those discontinuing 
tenofovir, with a change in slope at six months after discontinuation. In Model 2, we replaced 
the cubic spline with a straight line and in Model 3, we replaced both the cubic spline and 
piecewise linear spline with straight lines. 
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In all three models, we assumed patients on different regimens might have different 
baseline values after one year on tenofovir but that the subsequent rate of decline and 
recovery before and after discontinuing tenofovir would be the same regardless of regimen. 
We did not have sufficient data to estimate differences in the rate of decline and recovery 
between therapies in a single model. Therefore in two exploratory analyses, we re-fitted this 
sequence of three models first to only those patients starting tenofovir with EFV and second 
to only those patients starting tenofovir with either LPV/r or ATV/r (as these two drugs appear 
to have similar effects on eGFR [7,15] while little is known about the effect of DRV/r). 
We used SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) for all analyses. 
Results 
Patient flow 
As at May 2013, 1049 patients had taken tenofovir continuously for at least one year, with at 
least one calibrated serum creatinine measurement between 6 months and one year after 
starting therapy (and having started one of the four regimens of interest – Table 1). These 
1049 patients were then followed for a median of 26 months (IQR 13, 49). During this time, 
they had a median of 7 (IQR 3, 12) creatinine measurements with a median time between 
measurements of 3.3 months (IQR 2.8, 5.6). 
Of the 1049 patients, 888 (85%) had a creatinine measurement in the 6 months prior to 
starting therapy. Patients started all four regimens with a similar median eGFR but after one 
year on therapy, the median eGFR was slightly lower in those starting tenofovir with a PI/r 
(Table 1). From baseline at one year, 259 (25%) patients went on to discontinue tenofovir 
after an additional median time on tenofovir of 17 months (IQR 7, 34). Those starting therapy 
with LPV/r or ATV/r had a lower median eGFR when they discontinued tenofovir than those 
starting with EFV. Among the few patients (45, 4%) followed after discontinuing tenofovir for 
as long as they had been on tenofovir, eGFR returned to its pre-therapy median only in those 
patients that started tenofovir with EFV. 
Estimates of eGFR decline and recovery 
In Model 1, the estimated difference in eGFR slope between patients discontinuing tenofovir 
and patients remaining on tenofovir (Table 2) was not much greater in the first six months off 
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tenofovir (4.1, 95% confidence interval (CI) -1.0 to 9.3 [mL/min per 1.73 m2 per year]) than in 
the period beyond six months (3.0, 95% CI 1.8 to 4.3). This result suggests the difference was 
only slightly non-linear. These two estimates were not appreciable different when the flexible 
cubic spline representing the rate of decline in eGFR was replaced by a straight line (Model 
2). This result suggests that after one year on tenofovir, further decline in eGFR was 
approximately linear. Finally, assuming recovery was also approximately linear (Model 3) 
provided estimates of an approximate linear rate of both decline in eGFR on tenofovir (-1.1, 
95% CI -1.5 to -0.8) and its recovery after discontinuing tenofovir (2.1, 95% CI 1.3 to 2.9). 
In Model 1, patients starting tenofovir with DRV/r had similar eGFR at baseline to those 
starting tenofovir with EFV (estimated difference 0.0, 95% CI -1.7 to 1.7 [mL/min per 1.73 
m2]). There is some evidence patients starting tenofovir with LPV/r or ATV/r had a lower 
eGFR at baseline than those starting tenofovir with EFV (with estimated differences -0.7, 95% 
CI -2.3 to 0.8, and -1.4, 95% CI -3.2 to 0.3, respectively). 
In the two exploratory analyses, estimates of the rate of decline in eGFR and its 
recovery after discontinuing tenofovir were similar when the three models were fit to either 
only those patients starting tenofovir with EFV or only those patients starting tenofovir with 
either LPV/r or ATV/r (Table 2). 
Discussion 
It is important to understand how eGFR recovers when tenofovir is discontinued because in 
the future, patients on tenofovir may switch to new treatment combinations [16]. Our 
modelling of observational data suggests that after one year on tenofovir, the approximate 
rate of further decline in eGFR is about 1 mL/min per 1.73 m2 per year and is about half the 
approximate rate of recovery in eGFR if patients then discontinue taking tenofovir. This 
implies that most patients should recover pre-therapy renal function by the time they have 
been off tenofovir for as long as they were on it. Our data suggests this indeed happens, at 
least for patients starting tenofovir with EFV. For the 15 patients starting tenofovir with EFV 
and then remaining off tenofovir for as long as they were on it, the median difference between 
pre-therapy and post-recovery eGFR was 0.1 (IQR -9.4, 2.7) mL/min per 1.73 m2.  
For patients starting tenofovir with a PI/r, the picture is more complicated. In an earlier 
study, we found an initial decrease in eGFR when starting tenofovir with LPV/r or ATV/r rather 
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than with EFV, but no further decrease beyond the first six months of therapy [15]. And in this 
study, while patients starting tenofovir with LPV/r or ATV/r had lower eGFR at baseline (that 
is, after one year on tenofovir) than patients starting tenofovir with EFV, both groups of 
patients had a similar rate of decline in eGFR beyond one year and a similar rate of recovery 
when tenofovir was discontinued. 
However patients starting tenofovir with a PI/r did not appear to recover their pre-
therapy eGFR. For the 30 patients starting tenofovir with a PI/r and then remaining off 
tenofovir for as long as they were on it, the median difference between pre-therapy and post-
recovery eGFR was -7.9 (IQR -15.9, 3.6) mL/min per 1.73 m2. Of these 30 patients, 18 were 
still on a PI/r post-recovery. Ritonavir inhibits creatinine secretion [17] and the corresponding 
immediate but non-progressive increase in serum creatinine leads to a one-off decrease in 
eGFR [18]. Hence patients on tenofovir with LPV/r or ATV/r might still recover their true pre-
therapy glomerular filtration rate after discontinuing tenofovir without recovering their pre-
therapy eGFR. Analyses using eGFR must be interpreted with caution [18,19]: LPV/r and 
ATV/r are thought to increase the risk of renal impairment [7] but their contribution could be 
exaggerated when eGFR is used to assess that risk. 
Note that our estimated rate of decline in eGFR after one year is the same as the 
accepted “normal” decline in glomerular filtration rate with age (1 mL/min per 1.73 m2 per year 
[20]). However much of this “normal” decline has been attributed to comorbidities that 
inevitably accompany ageing [21-23]. This makes it difficult to judge how much tenofovir has 
contributed to the rate of decline in renal function in these patients. That the decline in eGFR 
reversed when tenofovir was discontinued suggests that tenofovir was responsible, at least in 
part, for the decline. 
This study has the same limitations as our earlier study [15]. In addition, we did not 
have sufficient data to estimate, in a single model, differences between regimens in the rate 
of decline in eGFR and its recovery if tenofovir is discontinued. This can be done using a 
marginal structural model but requires artificial censoring of patients when they change their 
baseline regimen [24,25] and this artificial censoring reduces the power of the analysis. The 
strengths of this study are the use of calibrated creatinine measurements and of statistical 
methods that minimise any bias due to time dependent confounding. 
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When monitoring eGFR in patients starting tenofovir with either EFV, LPV/r or ATV/r, 
clinicians can expect renal function to recover more rapidly than it declined if patients 
discontinue tenofovir. On average patients on a PI/r may not recover their pre-therapy eGFR 
after discontinuing tenofovir, but is not clear yet whether this has clinical consequences. While 
on average patients can be expected to recover their renal function after discontinuing 
tenofovir, not all patients will do so. 
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Table 1: A: Patient characteristics at one year after starting tenofovir (TDF) with either 
efavirenz (EFV) or the ritonavir-boosted protease inhibitors lopinavir (LPV/r), 
atazanavir (ATV/r) or darunavir (DRV/r), plus either emtricitabine or lamivudine.  
B: Patient flow before and after starting antiretroviral therapy and at each point, the 
corresponding median estimated glomerular filtration rate (eGFR) and interquartile 
range (IQR). 
 
 
A: Characteristics 
EFV 
n=501 
LPV/r 
n=219 
ATV/r 
n=189 
DRV/r 
n=140 
Median age, years 41 42 40 41 
Female gender, % 16 25 23 10 
Black ethnicity, % 15 13 11 6 
Intravenous drug use as the likely 
mode of transmission, % 
5 10 13 3 
Median time since HIV diagnosis, 
months 
23 15 32 14 
Advance infection (CDC Group C), % 14 30 14 18 
Hepatitis C co-infection, % 10 16 21 6 
Diabetes, % 5 3 3 1 
Hypertension, % 23 27 22 26 
Median HIV RNA, log10 copies/ml 1.3 1.6 1.5 1.3 
Median CD4 cell count, cells/mm3 421 412 428 465 
Median body mass index, kg/m2 24 23 24 24 
     
B: Patient flow     
Number of patients with eGFR measurements 
Prior to starting TDF 417 174 166 131 
One year after starting TDF 501 219 189 140 
Prior to stopping TDF 103 77 63 16 
Remaining off TDF for as long as 
having received TDF 
15 18 11 1 
Median eGFR, mL/min per 1.73 m2 (IQR) 
Prior to starting TDF 105 (93, 115) 106 (95, 115) 107 (95, 116) 107 (94, 118) 
One year after starting TDF 104 (94, 115) 102 (87, 111) 100 (85, 110) 100 (89, 111) 
Prior to stopping TDF 99 (83, 114) 94 (73, 109) 94 (76, 106) 103 (69, 112) 
Remaining off TDF for as long as 
having received TDF 
104 (71, 114) 95 (80, 110) 82 (73, 103) 84 (84, 84) 
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Table 2: Estimates of the decline and recovery in estimated glomerular filtration rate 
(eGFR) for patients starting tenofovir (TDF) with either efavirenz (EFV) or the 
ritonavir boosted protease inhibitors lopinavir (LPV/r), atazanavir (ATV/r) or 
darunavir, plus either emtricitabine or lamivudine. 
 
Model and rate parameters, All patients Patients starting Patients starting 
mL/min per 1.73 m2 per year  tenofovir with tenofovir with 
(95% confidence interval)  EFV LPV/r or ATV/r 
 n=1032 1 n=495 1 n=398 1 
Model 1    
Decline – cubic spline 5 knots Not available 2 Not available 2 Not available 2 
Time off TDF – first 6 months 4.1 (-1.0 to 9.3) 4.5 (-3.8 to 12.8) 4.8 (-1.8 to 11.4) 
Time off TDF  – after 6 months 3.0 (1.8 to 4.3) 3.3 (0.4 to 6.2) 2.7 (1.2 to 4.2) 
Model 2    
Linear rate of decline -1.2 (-1.5 to -0.8) -1.3 (-1.9 to -0.7) -1.1 (-1.5 to -0.7) 
Time off TDF – first 6 months 3.9 (-1.2  to 8.9) 4.5 (-3.7 to 12.6) 4.0 (-2.6 to 10.6) 
Time off TDF  – after 6 months 3.2 (1.8 to 4.4) 3.3 (0.4 to 6.2) 2.9 (1.3 to 4.5) 
Model 3    
Linear rate of decline -1.1 (-1.5 to -0.8) -1.3 (-1.9 to -0.7) -1.1 (-1.5 to -0.7) 
Time off TDF – at any time 3.3 (2.4 to 4.2) 3.5 (1.5 to 5.5) 3.1 (2.0 to 4.2) 
Linear rate of recovery 3 2.1 (1.3 to 2.9) 2.2 (0.3 to 4.2) 2.0 (1.0 to 3.0) 
1 The number of patients in each analysis is slightly lower than the corresponding number in 
Table 1 because a total of 17 patients had no further creatinine measurements after one 
year on tenofovir. 
2 No easily interpretable estimate is available for this model, because the rate of decline is 
represented by a flexible curve. 
3 Found by summing the previous two parameters (with a confidence interval found from the 
parameter variance covariance matrix). 
 
 
